“…However, HtrA1 is the first in the family to be implicated as a tumor suppressor in ovarian cancer and melanoma (3,5,13). In addition, HtrA1 is implicated in various pathogenic and developmental processes, including osteoarthritis, Alzheimer's disease, neuronal maturation and development, age-related macular degeneration, and tumor progression (11,23,24,33,36,50,56). Specific to its role in tumor progression, HtrA1 is downregulated in various cancers, and its downregulation is associated with resistance to chemotherapy and a metastatic phenotype (4,11,19).…”